Amyloid-β (1-40) and Mortality in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome: A Cohort Study
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
Abstract
Background:
Amyloid-β (1-40) (Aβ40) is implicated in mechanisms related to plaque destabilization and correlates with adverse outcomes in stable coronary artery disease.
Objective:
To determine the prognostic and reclassification value of baseline circulating levels of Aβ40 after adjustment for the Global Registry of Acute Coronary Events (GRACE) score, which is widely recommended for risk stratification in non–ST-segment elevation acute coronary syndrome (NSTE-ACS).
Design:
Retrospective cohort study using data from 2 independent prospective cohorts, the Heidelberg study (n = 1145) and the validation multicenter international APACE (Advantageous Predictors of Acute Coronary Syndrome Evaluation) study (n = 734).
Setting:
Academic hospitals in 7 European countries.
Participants:
Patients with adjudicated NSTE-ACS followed for a median of 21.9 and 24.9 months in the Heidelberg and APACE studies, respectively.
Measurements:
All-cause mortality was the primary end point.
Results:
Amyloid-β (1-40) was associated with mortality after multivariate adjustment for age, sex, diabetes mellitus, high-sensitivity cardiac troponin T and C-reactive protein, revascularization, and ACS type (Heidelberg cohort hazard ratio [HR] for 80th vs. 20th percentiles, 1.66 [95% CI, 1.06 to 2.61; P = 0.026]; APACE cohort HR, 1.50 [CI, 1.15 to 1.96; P = 0.003]). It was also associated with mortality after adjustment for the GRACE score (Heidelberg cohort HR for 80th vs. 20th percentiles, 1.11 [CI, 1.04 to 1.18; P = 0.001]; APACE cohort HR, 1.39 [CI, 1.02 to 1.88; P = 0.036]). Amyloid-β (1-40) correctly reclassified risk for death over the GRACE score (net reclassification index, 33.4% and 47.1% for the Heidelberg and APACE cohorts, respectively) (P < 0.05).
Limitation:
At low concentrations of Aβ40, dose–response associations with mortality differed between cohorts, possibly because of varying blood preparations used to measure Aβ40.
Conclusion:
Circulating Aβ40 is a predictor of mortality and improves risk stratification of patients with NSTE-ACS over the GRACE score recommended by clinical guidelines. The clinical application of Aβ40 as a novel biomarker in NSTE-ACS should be further explored and validated.
Primary Funding Source:
German Cardiac Society.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Bawamia B, Mehran R, Qiu W, Kunadian V. Risk scores in acute coronary syndrome and percutaneous coronary intervention: a review. Am Heart J. 2013;165:441-50. [PMID: 23537960] doi: 10.1016/j.ahj.2012.12.020
2.
Widera C, Pencina MJ, Meisner A, Kempf T, Bethmann K, Marquardt I, et al. Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome. Eur Heart J. 2012;33:1095-104. [PMID: 22199121] doi: 10.1093/eurheartj/ehr444
3.
Liu Y, Syed Z, Scirica BM, Morrow DA, Guttag JV, Stultz CM. ECG morphological variability in beat space for risk stratification after acute coronary syndrome. J Am Heart Assoc. 2014;3:e000981. [PMID: 24963105] doi: 10.1161/JAHA.114.000981
4.
Ohman EM, Harskamp RE. We need to do better for patients with non-ST-segment elevation acute coronary syndrome who are managed without revascularization [Editorial]. J Am Coll Cardiol. 2014;63:2258-60. [PMID: 24703912] doi: 10.1016/j.jacc.2014.03.009
5.
Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al; ESC Scientific Document Group. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267-315. [PMID: 26320110] doi: 10.1093/eurheartj/ehv320
6.
Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:2022-60. [PMID: 21444889] doi: 10.1161/CIR.0b013e31820f2f3e
7.
Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64:e139-228. [PMID: 25260718] doi: 10.1016/j.jacc.2014.09.017
8.
Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115-26. [PMID: 9887164]
9.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-95. [PMID: 15843671]
10.
Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481-8. [PMID: 15983262]
11.
Stellos K, Gatsiou A, Stamatelopoulos K, PerisicMatic L, John D, Lunella FF, et al. Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation. Nat Med. 2016;22:1140-50. [PMID: 27595325] doi: 10.1038/nm.4172
12.
Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333:1091. [PMID: 17032691]
13.
Aragam KG, Tamhane UU, Kline-Rogers E, Li J, Fox KA, Goodman SG, et al. Does simplicity compromise accuracy in ACS risk prediction? A retrospective analysis of the TIMI and GRACE risk scores. PLoS One. 2009;4:e7947. [PMID: 19956773] doi: 10.1371/journal.pone.0007947
14.
Abu-Assi E, Ferreira-González I, Ribera A, Marsal JR, Cascant P, Heras M, et al. “Do GRACE (Global Registry of Acute Coronary Events) risk scores still maintain their performance for predicting mortality in the era of contemporary management of acute coronary syndromes?”. Am Heart J. 2010;160:826-34. [PMID: 21095268] doi: 10.1016/j.ahj.2010.06.053
15.
Ng LL, Sandhu JK, Narayan H, Quinn PA, Squire IB, Davies JE, et al. Pro-substance P for evaluation of risk in acute myocardial infarction. J Am Coll Cardiol. 2014;64:1698-707. [PMID: 25323258] doi: 10.1016/j.jacc.2014.05.074
16.
Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 1999;399:A23-31. [PMID: 10392577]
17.
De Meyer GR, De Cleen DM, Cooper S, Knaapen MW, Jans DM, Martinet W, et al. Platelet phagocytosis and processing of beta-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis. Circ Res. 2002;90:1197-204. [PMID: 12065323]
18.
Van De Parre TJ, Guns PJ, Fransen P, Martinet W, Bult H, Herman AG, et al. Attenuated atherogenesis in apolipoprotein E-deficient mice lacking amyloid precursor protein. Atherosclerosis. 2011;216:54-8. [PMID: 21316678] doi: 10.1016/j.atherosclerosis.2011.01.032
19.
Van Nostrand WE, Schmaier AH, Farrow JS, Cunningham DD. Protease nexin-II (amyloid beta-protein precursor): a platelet alpha-granule protein. Science. 1990;248:745-8. [PMID: 2110384]
20.
Smith CC. Stimulated release of the beta-amyloid protein of Alzheimer's disease by normal human platelets. Neurosci Lett. 1997;235:157-9. [PMID: 9406893]
21.
Kitazume S, Yoshihisa A, Yamaki T, Oikawa M, Tachida Y, Ogawa K, et al. Soluble amyloid precursor protein 770 is released from inflamed endothelial cells and activated platelets: a novel biomarker for acute coronary syndrome. J Biol Chem. 2012;287:40817-25. [PMID: 23033480] doi: 10.1074/jbc.M112.398578
22.
Kitazume S, Tachida Y, Kato M, Yamaguchi Y, Honda T, Hashimoto Y, et al. Brain endothelial cells produce amyloid-β from amyloid precursor protein 770 and preferentially secrete the O-glycosylated form. J Biol Chem. 2010;285:40097-103. [PMID: 20952385] doi: 10.1074/jbc.M110.144626
23.
Simons M, Keller P, DeStrooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95:6460-4. [PMID: 9600988]
24.
Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277:813-7. [PMID: 9052711]
25.
Bu G, Cam J, Zerbinatti C. LRP in amyloid-beta production and metabolism. Ann N Y Acad Sci. 2006;1086:35-53. [PMID: 17185504]
26.
Stamatelopoulos K, Sibbing D, Rallidis LS, Georgiopoulos G, Stakos D, Braun S, et al. Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease. J Am Coll Cardiol. 2015;65:904-16. [PMID: 25744007] doi: 10.1016/j.jacc.2014.12.035
27.
Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007;28:2525-38. [PMID: 17951287]
28.
Wildi K, Cullen L, Twerenbold R, Greenslade JH, Parsonage W, Boeddinghaus J, et al. Direct comparison of 2 rule-out strategies for acute myocardial infarction: 2-h accelerated diagnostic protocol vs 2-h algorithm. Clin Chem. 2017;63:1227-36. [PMID: 28515106] doi: 10.1373/clinchem.2016.268359
29.
Nestelberger T, Boeddinghaus J, Badertscher P, Twerenbold R, Wildi K, Breitenbücher D, et al; APACE Investigators. Effect of definition on incidence and prognosis of type 2 myocardial infarction. J Am Coll Cardiol. 2017;70:1558-68. [PMID: 28935032] doi: 10.1016/j.jacc.2017.07.774
30.
Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest. 2007;117:3393-402. [PMID: 17965777]
31.
Abdullah L, Paris D, Luis C, Quadros A, Parrish J, Valdes L, et al. The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels. Neurosci Lett. 2007;428:53-8. [PMID: 17964720]
32.
Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem. 2010;56:254-61. [PMID: 19959623] doi: 10.1373/clinchem.2009.132654
33.
de Araújo Gonçalves P, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J. 2005;26:865-72. [PMID: 15764619]
34.
Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al; Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163:2345-53. [PMID: 14581255]
35.
Tang EW, Wong CK, Herbison P. Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome. Am Heart J. 2007;153:29-35. [PMID: 17174633]
36.
Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med. 2010;29:1037-57. [PMID: 20087875] doi: 10.1002/sim.3841
37.
Ng LL, Sandhu JK, Narayan H, Quinn PA, Squire IB, Davies JE, et al. Proenkephalin and prognosis after acute myocardial infarction. J Am Coll Cardiol. 2014;63:280-9. [PMID: 24140658] doi: 10.1016/j.jacc.2013.09.037
38.
Mueller C, Buettner HJ, Hodgson JM, Marsch S, Perruchoud AP, Roskamm H, et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation. 2002;105:1412-5. [PMID: 11914246]
39.
Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000;343:1139-47. [PMID: 11036119]
40.
Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002;106:2913-8. [PMID: 12460871]
41.
Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11-21. [PMID: 21204120] doi: 10.1002/sim.4085
42.
Pencina MJ, D'Agostino RB, Pencina KM, Janssens AC, Greenland P. Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol. 2012;176:473-81. [PMID: 22875755]
43.
Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-72. [PMID: 17569110]
44.
van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18:681-94. [PMID: 10204197]
45.
Liu YH, Xiang Y, Wang YR, Jiao SS, Wang QH, Bu XL, et al. Association between serum amyloid-beta and renal functions: implications for roles of kidney in amyloid-beta clearance. Mol Neurobiol. 2015;52:115-9. [PMID: 25119777] doi: 10.1007/s12035-014-8854-y
46.
Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al; GRACE Investigators. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291:2727-33. [PMID: 15187054]
47.
Farooq V, Vergouwe Y, Généreux P, Bourantas CV, Palmerini T, Caixeta A, et al. Prediction of 1-year mortality in patients with acute coronary syndromes undergoing percutaneous coronary intervention: validation of the logistic clinical SYNTAX (Synergy Between Percutaneous Coronary Interventions With Taxus and Cardiac Surgery) score. JACC Cardiovasc Interv. 2013;6:737-45. [PMID: 23866185] doi: 10.1016/j.jcin.2013.04.004
48.
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-31. [PMID: 28845751] doi: 10.1056/NEJMoa1707914
49.
Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov. 2010;9:387-98. [PMID: 20431570] doi: 10.1038/nrd2896
50.
Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98:5856-61. [PMID: 11296263]
51.
Wang J, Zhao Z, Lin E, Zhao W, Qian X, Freire D, et al. Unintended effects of cardiovascular drugs on the pathogenesis of Alzheimer's disease. PLoS One. 2013;8:e65232. [PMID: 23762322] doi: 10.1371/journal.pone.0065232
52.
Rubio I, Caramelo C, Gil A, López MD, de Yébenes JG. Plasma amyloid-beta, Abeta1-42, load is reduced by haemodialysis. J Alzheimers Dis. 2006;10:439-43. [PMID: 17183156]
53.
Li L, Cao D, Garber DW, Kim H, Fukuchi K. Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. Am J Pathol. 2003;163:2155-64. [PMID: 14633589]
54.
Ahn HJ, Glickman JF, Poon KL, Zamolodchikov D, Jno-Charles OC, Norris EH, et al. A novel Aβ-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice. J Exp Med. 2014;211:1049-62. [PMID: 24821909] doi: 10.1084/jem.20131751
55.
Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C. A beta-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol. 2001;281:H2417-24. [PMID: 11709407]
56.
Chisari M, Merlo S, Sortino MA, Salomone S. Long-term incubation with beta-amyloid peptides impairs endothelium-dependent vasodilatation in isolated rat basilar artery. Pharmacol Res. 2010;61:157-61. [PMID: 19782136] doi: 10.1016/j.phrs.2009.09.004
57.
Chong YH, Sung JH, Shin SA, Chung JH, Suh YH. Effects of the beta-amyloid and carboxyl-terminal fragment of Alzheimer's amyloid precursor protein on the production of the tumor necrosis factor-alpha and matrix metalloproteinase-9 by human monocytic THP-1. J Biol Chem. 2001;276:23511-7. [PMID: 11306564]
58.
Sonkar VK, Kulkarni PP, Dash D. Amyloid β peptide stimulates platelet activation through RhoA-dependent modulation of actomyosin organization. FASEB J. 2014;28:1819-29. [PMID: 24421399] doi: 10.1096/fj.13-243691
59.
Lloyd-Jones DM, Martin DO, Larson MG, Levy D. Accuracy of death certificates for coding coronary heart disease as the cause of death. Ann Intern Med. 1998;129:1020-6. [PMID: 9867756]
60.
Fox CS, Evans JC, Larson MG, Lloyd-Jones DM, O'Donnell CJ, Sorlie PD, et al. A comparison of death certificate out-of-hospital coronary heart disease death with physician-adjudicated sudden cardiac death. Am J Cardiol. 2005;95:856-9. [PMID: 15781015]
61.
Hall M, Dondo TB, Yan AT, Goodman SG, Bueno H, Chew DP, et al. Association of clinical factors and therapeutic strategies with improvements in survival following non-ST-elevation myocardial infarction, 2003-2013. JAMA. 2016;316:1073-82. [PMID: 27574717] doi: 10.1001/jama.2016.10766
62.
Bibl M, Welge V, Esselmann H, Wiltfang J. Stability of amyloid-β peptides in plasma and serum. Electrophoresis. 2012;33:445-50. [PMID: 22287174] doi: 10.1002/elps.201100455
63.
Ahn HJ, Zamolodchikov D, Cortes-Canteli M, Norris EH, Glickman JF, Strickland S. Alzheimer's disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Proc Natl Acad Sci U S A. 2010;107:21812-7. [PMID: 21098282] doi: 10.1073/pnas.1010373107
64.
Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002;359:1686-9. [PMID: 12020548]
65.
Stone C, Koo C. Additive Splines in Statistics Proceedings of the Statistical Computing Section. Alexandria, VA: American Statistical Association; 1985.
66.
Wald A. Sequential tests of statistical hypotheses. The Annals of Mathematical Statistics. 1945;16:117-86.
67.
Nelder JA, Wedderburn RWM. Generalized linear models. J R Stat Soc Ser A Stat Soc. 1972;135:370-84.
68.
McCullagh P, Nelder JA. Generalized Linear Models. 2nd ed. London: Chapman & Hall; 1989.
Information & Authors
Information
Published In
Annals of Internal Medicine
Volume 168 • Number 12 • 19 June 2018
Pages: 855 - 865
History
Published online: 22 May 2018
Published in issue: 19 June 2018
Keywords
Copyright
© 2018 American College of Physicians.
Authors
Metrics & Citations
Metrics
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
Download article citation data for:
Amyloid-β (1-40) and Mortality in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome: A Cohort Study. Ann Intern Med.2018;168:855-865. [Epub 22 May 2018]. doi:10.7326/M17-1540
Amyloid-β (1-40) and Mortality in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome: A Cohort Study. Ann Intern Med.2018;168:855-865. [Epub 22 May 2018]. doi:10.7326/M17-1540
View More
Login Options:
Purchase
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
Access to EPUBs and PDFs for FREE Annals content requires users to be registered and logged in. A subscription is not required. You can create a free account below or from the following link. You will be redirected to acponline.org to create an account that will provide access to Annals. If you are accessing the Free Annals content via your institution's access, registration is not required.
Create your Free Account
You will be redirected to acponline.org to create an account that will provide access to Annals.
Comments
0 Comments